Abstract
There are several biologics approved in Russia to treat active radiographic axial spondyloarthritis (r-AxSpA). However, published clinical trial results differ in terms of placebo response. Along with significant financial burden of therapy, it poses a challenge to treatment decision-making. Number needed to treat (NNT) as a measure to compare the benefits of various treatments over a baseline risk helps to incorporate efficacy results into clinical practice.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
